Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2017

Publisher Name :
Date: 16-Aug-2017
No. of pages: 163
Inquire Before Buying

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2017, provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) pipeline landscape.

Attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness. Symptoms of ADHD include disorganized work habits, procrastination and inability to sustain attention on tasks or activities. Treatment includes analeptics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 5, 10, 8, 15, 6 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 2 molecules, respectively.

Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2017

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Attention Deficit Hyperactivity Disorder (ADHD) - Overview 8
Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 15
Products under Development by Universities/Institutes 18
Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Assessment 19
Assessment by Target 19
Assessment by Mechanism of Action 22
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development 29
4P-Pharma SAS 29
Aevi Genomic Medicine Inc 29
Alcobra Ltd 30
Amarantus Bioscience Holdings Inc 30
APeT Holding BV 31
BCWorld Pharm Co Ltd 31
BioHealthonomics Inc 32
Cingulate Therapeutics LLC 32
Collegium Pharmaceutical Inc 33
Curemark LLC 33
DURECT Corp 34
Eli Lilly and Company 34
H. Lundbeck A/S 35
Heptares Therapeutics Ltd 35
Highland Therapeutics Inc 36
KemPharm Inc 36
Luc Therapeutics Inc 37
Merck & Co Inc 37
Neos Therapeutics Inc 38
NeuroDerm Ltd 38
Novartis AG 39
Noven Pharmaceuticals Inc 39
Otsuka Pharmaceutical Co Ltd 40
P2D Bioscience 40
Reviva Pharmaceuticals Inc 41
Shire Plc 41
SK Biopharmaceuticals Co Ltd 42
Sunovion Pharmaceuticals Inc 42
Supernus Pharmaceuticals Inc 43
Taisho Pharmaceutical Holdings Co Ltd 43
Tris Pharma Inc 44
Attention Deficit Hyperactivity Disorder (ADHD) - Drug Profiles 45
(nicotine + opipramol hydrochloride) - Drug Profile 45
4-P003 - Drug Profile 47
amfetamine XR - Drug Profile 48
BCWPE-003 - Drug Profile 49
BNC-375 - Drug Profile 50
CB-8411 - Drug Profile 52
centanafadine SR - Drug Profile 53
CM-4612 - Drug Profile 56
dasotraline hydrochloride - Drug Profile 57
dexmethylphenidate hydrochloride - Drug Profile 61
dextroamphetamine - Drug Profile 62
dextroamphetamine - Drug Profile 64
dextroamphetamine IR - Drug Profile 65
dextroamphetamine MR - Drug Profile 66
edivoxetine hydrochloride - Drug Profile 68
eltoprazine - Drug Profile 70
fasoracetam - Drug Profile 75
histamine dihydrochloride - Drug Profile 78
HTL-1071 - Drug Profile 79
INV-107 - Drug Profile 81
KP-415 CR - Drug Profile 82
KP-484 - Drug Profile 84
levofacetoperane - Drug Profile 85
lisdexamfetamine dimesylate - Drug Profile 86
mazindol CR - Drug Profile 93
methylphenidate ER - Drug Profile 96
methylphenidate hydrochloride MR - Drug Profile 97
methylphenidate hydrochloride SR - Drug Profile 102
modafinil - Drug Profile 104
molindone hydrochloride ER - Drug Profile 105
niacinamide CR - Drug Profile 107
NLS-4 - Drug Profile 108
NLS-8 - Drug Profile 109
P-001 - Drug Profile 110
PBF-509 - Drug Profile 111
PD-2005 - Drug Profile 113
PD-3044 - Drug Profile 114
PFR-08001 ER - Drug Profile 115
PFR-8026 - Drug Profile 116
RP-5063 - Drug Profile 117
SERx-480 - Drug Profile 119
SKL-ADHD - Drug Profile 120
Small Molecule to Block Dopamine, Norepinephrine and Serotonin Transporter for Attention Deficit Hyperactivity Disorder - Drug Profile 121
Small Molecules to Activate High Affinity Choline Transporter for Attention Deficit Hyperactivity Disorder - Drug Profile 122
Small Molecules to Agonize NMDA2D for Attention Deficit Hyperactivity Disorder - Drug Profile 123
Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile 124
Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile 125
Small Molecules to Inhibit Sodium Hydrogen Exchanger for ADHD - Drug Profile 126
Synthetic Peptide to Antagonize D2 for ADHD - Drug Profile 127
TAH-9901 - Drug Profile 128
TRN-110 - Drug Profile 129
TS-141 - Drug Profile 130
Vaccine for CNS Disorders - Drug Profile 131
viloxazine hydrochloride ER - Drug Profile 132
vortioxetine hydrobromide - Drug Profile 134
VU-0238429 - Drug Profile 140
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects 141
Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products 145
Attention Deficit Hyperactivity Disorder (ADHD) - Product Development Milestones 146
Featured News & Press Releases 146
Appendix 158
Methodology 158
Coverage 158
Secondary Research 158
Primary Research 158
Expert Panel Validation 158
Contact Us 158
Disclaimer 159

List of Tables
Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by 4P-Pharma SAS, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Aevi Genomic Medicine Inc, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Alcobra Ltd, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Amarantus Bioscience Holdings Inc, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by APeT Holding BV, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BCWorld Pharm Co Ltd, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BioHealthonomics Inc, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Cingulate Therapeutics LLC, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Collegium Pharmaceutical Inc, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Curemark LLC, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by DURECT Corp, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Eli Lilly and Company, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by H. Lundbeck A/S, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Heptares Therapeutics Ltd, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Highland Therapeutics Inc, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by KemPharm Inc, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Luc Therapeutics Inc, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Merck & Co Inc, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Neos Therapeutics Inc, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by NeuroDerm Ltd, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Novartis AG, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Noven Pharmaceuticals Inc, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Otsuka Pharmaceutical Co Ltd, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by P2D Bioscience, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Reviva Pharmaceuticals Inc, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Shire Plc, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Sunovion Pharmaceuticals Inc, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Supernus Pharmaceuticals Inc, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Tris Pharma Inc, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H2 2017 (Contd..1), H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H2 2017 (Contd..2), H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H2 2017 (Contd..3), H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
  • Mild Cognitive Impairment - Pipeline Review, H2 2017
    Published: 12-Sep-2017        Price: US 2000 Onwards        Pages: 113
    Mild Cognitive Impairment - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mild Cognitive Impairment - Pipeline Review, H2 2017, provides an overview of the Mild Cognitive Impairment (Central Nervous System) pipeline landscape. Mild cognitive impairment (MCI) is a condition involving problems with cognitive function (such as thinking, knowing and remembering). MCI is an intermediate s......
  • Dyskinesia - Pipeline Review, H2 2017
    Published: 12-Sep-2017        Price: US 2000 Onwards        Pages: 147
    Dyskinesia - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyskinesia - Pipeline Review, H2 2017, provides an overview of the Dyskinesia (Central Nervous System) pipeline landscape. Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive ......
  • Global Gabapentin Market Professional Survey Report 2017
    Published: 05-Sep-2017        Price: US 3500 Onwards        Pages: 105
    This report studies Gabapentin in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Pfizer - GSK - Sailike - Jiangsu Enhua - Jiangsu Hengrui - ......
  • Global Learning Disability Partnering 2010 to 2017
    Published: 01-Sep-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." The Global Learning Disability Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - Top deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type The report provides......
  • Global Smoking Cessation Partnering 2010 to 2017
    Published: 01-Sep-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." The Global Smoking Cessation Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - Top deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type The report provides u......
  • Global Neuralgia Partnering 2010-2017
    Published: 01-Sep-2017        Price: US 1495 Onwards        Pages: 150
    "Delivery of this report will take 1-3 days after purchase." The Global Neuralgia Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - Top deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type The report provides understan......
  • Global Attention Deficit Disorder Partnering 2010-2017
    Published: 01-Sep-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." The Global Attention Deficit Disorder Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - Top deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type The report p......
  • Global Autism Partnering 2010-2017
    Published: 01-Sep-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." The Global Autism Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - Top deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type The report provides understandin......
  • Global Traumatic Brain Injury Partnering 2010 to 2017
    Published: 01-Sep-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." The Global Traumatic Brain Injury Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - Top deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type The report provi......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs